Gain Therapeutics, Inc.
We are a development-stage biotechnology company developing novel therapeutics to treat rare genetic diseases and neurological disorders caused by protein misfolding, with an initial focus on lysosomal storage disorders (“LSDs”). We use our exclusively in-licensed proprietary platform, Site-Directed Enzyme Enhancement Therapy (“SEE-Tx”), to discover novel allosteric sites on misfolded proteins and identify proprietary small molecules that bind these sites and restore protein folding, potentially treating the underlying disease. While the SEE-Tx platform is novel and has not been used to develop approved drugs yet, these advantages have the potential to ultimately enhance both tolerability and response.
As of Feb. 19, 2021, we have filed three patent applications and one provisional patent application (such applications do not cover the United States) for our novel Structurally Targeted Allosteric Regulators (“STARs”), which are small molecules with the potential to treat diseases with high unmet medical need for which there arefew or no available therapies. These diseases include Morquio B, GM1 Gangliosidosis (GM1), neuronopathic Gaucher disease, GBA1 Parkinson’s disease, Krabbe disease and Mucopolysaccharidosis type 1.
|Address||4800 Hampden Lane, Suite 200 Bethesda, MD 20814|
|Phone Number||(301) 500-1556|
|View Prospectus:||Gain Therapeutics, Inc.|
|Revenues||$0 mil (last 12 months)|
|Net Income||$-3.58 mil (last 12 months)|
|Price range||$0.00 - $0.00|
|Est. $ Volume||$40.0 mil|
|Manager / Joint Managers||BTIG/Oppenheimer & Co.|
|CO-Managers||National Securities Corp.|
|Expected To Trade:|
|Quiet Period Expiration Date:||Available only to Subscribers|
|Lock-Up Period Expiration Date:||Available only to Subscribers|
|SCOOP Rating||Available only to Subscribers|
|Rating Change||Available only to Subscribers|